Ovarian cancer is not automatically terminal, but the answer depends heavily on the stage at diagnosis and how the cancer responds to treatment. About 54% of cases are found after the cancer has already spread beyond the ovaries, which makes it harder to cure. Even so, the five-year survival rate for distant-stage ovarian cancer is 31.5%, and newer therapies are pushing those numbers higher for certain patients. Some women live for many years with the disease, sometimes through a cure, sometimes by managing it as a chronic condition with periods of remission and retreatment.
Why Stage at Diagnosis Matters So Much
Ovarian cancer is often called a “silent” disease because early symptoms, like bloating, pelvic discomfort, and feeling full quickly, overlap with everyday complaints. There is no reliable screening test for the general population, so most cases are caught late. More than half of all ovarian cancers have already spread to distant sites by the time they’re diagnosed.
When ovarian cancer is found early and confined to the ovary, the outlook is dramatically better. But the reality is that most patients are dealing with advanced disease from the start. That said, “advanced” does not mean “nothing can be done.” Treatment for advanced ovarian cancer has changed substantially in the last decade, and many patients live years beyond their initial diagnosis.
Survival Rates by Stage
According to the National Cancer Institute’s SEER database, which tracks cancer outcomes across the United States, the five-year relative survival rate for ovarian cancer that has spread to distant sites is 31.5%. That means roughly one in three women with metastatic ovarian cancer is alive five years after diagnosis. For cancer still localized to the ovary, five-year survival is significantly higher.
These numbers reflect outcomes from patients diagnosed between 2016 and 2022 and include women treated with older approaches. Newer targeted therapies, particularly for women with specific genetic profiles, are producing results that outpace these averages considerably.
How Genetics Change the Outlook
One of the most important factors in ovarian cancer prognosis is whether the tumor carries a BRCA1 or BRCA2 mutation. These mutations, present in roughly 15% to 20% of ovarian cancers, actually improve the cancer’s response to certain treatments.
Women with BRCA2 mutations have notably better outcomes in the first several years. A matched cohort study found that BRCA2 carriers had a 59% lower risk of death compared to women without these mutations during the first six years after diagnosis. BRCA1 carriers also had a 30% lower risk of death during that same window. The tumors in these patients tend to respond more strongly to platinum-based chemotherapy and to a class of drugs called PARP inhibitors that exploit the cancer cell’s inability to repair its own DNA.
One important nuance: these survival advantages are strongest in the early years. After about six years, the benefit levels off, and BRCA2 carriers may actually face a higher risk of late recurrence. This means genetic testing at diagnosis is critical for shaping the treatment plan and setting realistic expectations over time.
PARP Inhibitors and Long-Term Survival
The introduction of PARP inhibitors has been the single biggest shift in ovarian cancer treatment in recent years. These drugs work by blocking a DNA repair pathway that cancer cells rely on, especially in BRCA-mutated tumors.
The results from a landmark trial published in the Journal of Clinical Oncology are striking. Among women with newly diagnosed advanced ovarian cancer and a BRCA mutation, 67% of those who received a PARP inhibitor as maintenance therapy were alive at seven years, compared to 46.5% of those who received a placebo. Nearly half of the women on the PARP inhibitor (45.3%) were alive at seven years and had not needed any additional treatment, suggesting durable remission or possibly cure for a meaningful portion of patients.
The median time before patients needed a second round of treatment was over seven and a half years with the PARP inhibitor, compared to about three and a half years without it. These are not small differences. For a disease that was once considered universally fatal within a few years of advanced diagnosis, seven-year survival rates approaching 70% represent a genuine transformation.
What Happens When Cancer Comes Back
Most women with advanced ovarian cancer will experience a recurrence at some point, and when and how the cancer returns determines what comes next. The key distinction is how much time has passed since completing chemotherapy.
If the cancer returns more than six months after finishing platinum-based chemotherapy, it is considered “platinum sensitive.” These patients respond well to retreatment, with response rates between 70% and 90%. Many go through multiple cycles of treatment and remission over years, which is why oncologists increasingly describe recurrent ovarian cancer as a chronic disease rather than a terminal one.
If the cancer returns within six months of chemotherapy, it is classified as “platinum resistant.” This is a harder situation. Response rates to additional chemotherapy drop to between 5% and 30%, and median survival from the point of resistance is roughly 10 months. For these patients, the focus often shifts toward quality of life, symptom management, and honest conversations about goals of care.
Immunotherapy: Progress, but Slowly
Immunotherapy has revolutionized treatment for melanoma, lung cancer, and several other cancers, but ovarian cancer has proven more resistant to this approach. When used alone, immune checkpoint drugs produce response rates of only about 6% to 15% in ovarian cancer patients.
Combination approaches are more promising. Pairing an immune checkpoint drug with a blood vessel-targeting drug yielded response rates near 29% in one trial, and a three-drug combination achieved a 47.5% response rate. These are not standard treatments yet, but they represent genuine progress for women who have run out of other options. Researchers are also exploring cancer vaccines designed to train the immune system to recognize ovarian cancer cells, though these remain in clinical trials.
Living With Ovarian Cancer as a Chronic Condition
For many women, the trajectory of ovarian cancer is not a steady decline but a series of treatments, remissions, and recurrences that can span years or even a decade or more. Major cancer centers now frame advanced ovarian cancer treatment with the goal of controlling disease and maintaining quality of life across these cycles.
This looks different for every patient. Some women return to work and normal activities between treatment rounds. Others deal with cumulative side effects from repeated chemotherapy, including fatigue, nerve damage in the hands and feet, and digestive issues. The emotional toll of living with a cancer that may come back is significant, and support for mental health and daily functioning is as important as the medical treatment itself.
Newer surgical approaches also play a role. Procedures that combine tumor removal with heated chemotherapy delivered directly into the abdomen can help control advanced disease while preserving quality of life, offering another tool for patients whose cancer has recurred.
When Treatment Shifts to Comfort Care
There are points in the disease where continuing aggressive treatment no longer offers meaningful benefit. Recognizing this transition is one of the hardest parts of living with ovarian cancer. The clinical markers that typically signal this shift include needing help with basic daily activities like bathing, dressing, or getting out of bed; unintentional weight loss of more than 10% of body weight over six months; recurrent serious infections; worsening shortness of breath; and persistent nausea or inability to eat.
For women with platinum-resistant disease and a limited expected survival, research has found that many patients themselves would prefer to transition from further chemotherapy to palliative care when median survival drops below five months. Hospice and palliative care are not about giving up. They focus on pain control, comfort, emotional support, and helping patients spend their remaining time the way they choose. Patients can often still receive limited treatments aimed at relieving symptoms while on hospice.
The Bottom Line on Prognosis
Ovarian cancer is serious, and advanced cases remain difficult to cure. But calling it universally terminal is no longer accurate. A woman diagnosed today with advanced ovarian cancer and a BRCA mutation has roughly a two-in-three chance of being alive seven years later with the right maintenance therapy. Even without favorable genetics, one in three women with distant-stage disease is alive at five years. The gap between “terminal” and “chronic but manageable” depends on the biology of the tumor, the timing of recurrence, and increasingly, access to newer targeted treatments.